While there is currently no cure for diabetes, we believe our anti-aging glycopeptide, AAGP®, may be the essential link to the successful treatments of tomorrow. In preliminary testing, AAGP® has been shown to have protective properties that could help with the causes and consequences of this difficult disease.

If you are interested in getting involved in what could be the next medical breakthrough in diabetes research, you’ve come to the right place. In this blog post, we’ve outlined the ways AAGP® could be used to support patients with diabetes as well as ways you can get invested in the progress that comes next.

How AAGP® could help patients living with type-1 diabetes

Islet cell transplants

To transform glucose into energy, our bodies rely on a hormone produced in the pancreas known as insulin. If our bodies don’t properly produce or utilize insulin, glucose can stay in our blood and cause health challenges over time.

Currently, islet cell transplants – which are used to support insulin production in the pancreas of diabetes patients – require anti-rejection medicines with harsh side effects. AAGP® could help prevent transplanted cell death and may even prevent the need for anti-rejection drugs.

Research surrounding islet cell transplants is currently in progress by the Shapiro group, led by Dr. James Shapiro, a ProtoKinetix principal investigator.

Retinal cell transplants

When our bodies do not properly metabolize glucose – as is the case with type-1 diabetes – our eyes can ulcer and become damaged without the ability to heal. The deterioration of retinas, rods, cones and blood vessels behind the eye can eventually lead to blindness.

Researchers led by Dr. Kevin Gregory-Evans are working to overcome the ocular side-effects associated with diabetes. For diabetic patients who experience retinal damage and vision loss related to diabetes, AAGP® may be used to help regenerate retinal cells and improve patient vision over time.

Reasons to believe AAGP® is a viable investment

In the realm of biotech research and development, progress takes time. It is important to understand that supporting ProtoKinetix and AAGP® is not a get-rich-quick scheme. It is a long-term investment in the future of improved medical treatment options.

We are looking for patient investors who are aware of the financial and time commitments required for medical research, and investors who believe in the potential of AAGP® for type-1 diabetes and are willing to see the impact through. While ProtoKinetix has made great strides in moving our research forward, we recognize there is still work to be done before we can uncover the true market potential.

Read about our recent progress, where we are in our research today and where we are heading next:

• ProtoKinetix Ready to Ship AAGP® to the University of Alberta for the Continuation of Phase 1 Human Trials
• Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada
• ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial
• ProtoKinetix files for patent protection for the use of AAGP® in transplant medicine
• ProtoKinetix AAGP® Retinal Cell Replacement Therapy Testing at UBC Completed

Hear from our longstanding investors

Become part of this exciting journey

If you are interested in investing in the potential of AAGP® to improve diabetes treatment options, please talk to your broker or contact the team at ProtoKinetix about an investment. Whether you are an individual with a personal connection to diabetes or a biomedical organization searching for the next medical breakthrough, we should talk.

This is an exciting, important opportunity that is not likely to come around again. Improving the treatment options for type-1 diabetes would not only have massive market potential, it would improve the lives of millions of individuals living with diabetes. We hope you’ll join us.